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Abstract Amiodarone is an eﬀective anti-arrhythmic
agent for the treatment of supraventricular and ventric-
ular tachycardias. The safety and eﬃcacy of intravenous
amiodarone has been described in adults and children
but only to a limited extent in infants. The purpose of this
study was to evaluate the safety and eﬃcacy of intrave-
nous amiodarone in infants. Between February 1994 and
June 2001, 23 infants with a median age of 8 days (range
1–300 days) with life-threatening incessant tachycardias
(17 supraventricular, 6 ventricular) were treated with
intravenous amiodarone as single anti-arrhythmic agent.
At presentation, 22 infants were haemodynamically
unstable. Amiodarone was given as an intravenous
loading dose of 5 mg/kg over 1 h followed by an intra-
venous maintenance dose of 5 lg/kg per min with step-
wise increase up to 25 lg/kg per min until arrhythmia
control or side-eﬀects occurred. Amiodarone was eﬀec-
tive in 19 infants, partially eﬀective in three and ineﬀec-
tive in one infant. The median time until arrhythmia
control was 24 h (range 1–96 h) and the median main-
tenance dosage 15 lg/kg per min (range 5–26 lg/kg per
min). Electrophysiological side-eﬀects necessitating dose
reduction comprised of sinus bradycardia in two pa-
tients. Hypotension in one patient resolved after dose
diminution. Neurological side-eﬀects consisted of cho-
reatic movements in one infant, which resolved over
time. Amiodarone administration was stopped in one
patient with elevated liver enzymes. Conclusion: Intra-
venous amiodarone is a safe and eﬀective therapy for life-
threatening incessant tachycardias in infants.
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Introduction
Amiodarone has been found to be eﬀective in the
treatment of supraventricular and ventricular tachycar-
dias in adult and paediatric patients [2, 8,9]. Various
studies have demonstrated the superior anti-arrhythmic
eﬀect of amiodarone compared to other anti-arrhythmic
agents [2, 3, 8,9]. Moreover, unlike other anti-arrhyth-
mic drugs, amiodarone has a low negative inotropic
eﬀect and can be safely used in patients with decreased
contractility and end-stage heart failure [1, 3, 4, 6, 7,10].
Amiodarone-related side-eﬀects are less pronounced in
paediatric patients than in adults [1,6]. Because of its
anti-arrhythmic eﬃcacy and low negative inotropic
eﬀect, intravenous amiodarone has been used in children
with life-threatening supraventricular or ventricular
tachycardias [3, 4,7]. Thus, intravenous amiodarone may
be the preferred anti-arrhythmic treatment for infants
and children with depressed myocardial function due to
incessant tachycardias or tachycardias arising in the
perioperative period of surgery for congenital heart
disease. Besides the potentially faster anti-arrhythmic
eﬀect, intravenous drug administration may also be
prompted by the inability of an oral route in infants and
children with severe heart failure or after previous car-
diac surgery [2]. However, there are concerns about the
safety of intravenous amiodarone, which also contains
chemicals with negative inotropic and hypotensive
eﬀects in the solution [2, 5,11]. Moreover, there is a
possibly more negative inotropic eﬀect of amiodarone
on the developing myocardium due to calcium channel
blocking activity [2]. Previous studies have also shown
that acute eﬀects of amiodarone on the electrophysio-
logical properties are diﬀerent in the neonatal and adult
cardiac ﬁbre [13].
Reports about the administration of intravenous
amiodarone in infants are scarce. The aim of the present
study was to determine the safety and eﬃcacy of intra-
venous amiodarone in infants for the treatment of
incessant tachycardias.
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Subjects and methods
Subjects
This study is a retrospective analysis of data from 23 infants (15
males, 8 females) who were treated from February 1994 to June
2001, with intravenous amiodarone. Characteristics of the group
are listed in Table 1. The majority of patients was in respiratory
distress and showed haemodynamic instability requiring ventila-
tion and cardiovascular support. Only one patient who was
followed for ventricular premature beats in the neonatal period
was asymptomatic and presented with incessant monomorphic
ventricular tachycardia. Compliant with other published recom-
mendations, intravenous amiodarone was used as single anti-
arrhythmic agent for infants with incessant monomorphic and
polymorphic ventricular tachycardias, incessant supraventricular
tachycardias with an ejection fraction <45% or infants in the
post-operative period after congenital heart surgery with com-
promised haemodynamics necessitating cardiopulmonary support
[3, 4, 7,9]. Treated arrhythmias were supraventricular tachycar-
dias in 17 and ventricular tachycardias in 6 infants (Table 2). All
arrhythmias were diagnosed by standard 12-lead ECG or ECG
derived from the intensive care unit monitoring system with the
addition of oesophageal or temporary pacing wire ECG in case
standard ECGs were not conclusive. Intravenous amiodarone
was administered under continuous intensive care unit ECG
monitoring and daily 12-lead ECG recordings to conﬁrm
arrhythmia control and to exclude pro-arrhythmic drug side-ef-
fects and QTc prolongation. After replacement of intravenous
amiodarone by oral amiodarone, patients were followed at 3
months intervals with 12-lead ECG, 24 h Holter monitoring, li-
ver and thyroid function tests.
Fetal arrhythmias were observed in four patients but were
not treated before birth. Only one patient with an atrioventric-
ular re-entrant tachycardia had previously received a class 1c
anti-arrhythmic agent that did not control the arrhythmia but
worsened the haemodynamic situation. Adenosine was adminis-
tered in patients with atrioventricular re-entrant tachycardias but
sporadic tachycardia terminations were always followed by near
immediate tachycardia re-initiations. Two infants with atrial
ﬁbrillation and intra-atrial re-entrant tachycardia respectively
were treated with intravenous amiodarone after D/C cardiover-
sion or overdrive pacing failed. However, in three infants with
observed on/oﬀ phenomenon of intra-atrial re-entrant tachycar-
dias, intravenous amiodarone was administered as ﬁrst line
therapy.
Drug administration protocol
Published protocols for intravenous amiodarone in paediatric
patients were adjusted concerning the maximum maintenance
dosage based on reports indicating the need for higher oral dosages
in children compared to adults [1, 3, 4, 7, 8,14]. After an intrave-
nous amiodarone loading dose of 5 mg/kg over 1 h, an initial
intravenous maintenance dose of 5 lg/kg per min was increased
every 6 h in 2.5 lg/kg per min steps up to 25 lg/kg per min until
the arrhythmia was controlled or pro-arrhythmic or haemody-
namic side-eﬀects occurred. Intravenous amiodarone was replaced
by oral amiodarone when oral feeding was tolerated in infants with
controlled arrhythmias. To avoid the risk of arrhythmia recur-
rences, no attempts were made in patients with amiodarone con-
trolled arrhythmias to switch to other anti-arrhythmic agents at the
time of change to oral amiodarone. A drug loading phase of
approximately 10 mg/kg amiodarone daily for 10 days was in-
tended for intravenous as well as combined intravenous and oral
administration. Oral amiodarone therapy was then continued for
about 1 year.
Deﬁnition of drug eﬃcacy, pro-arrhythmia and side-eﬀects
As described previously, anti-arrhythmic therapy was considered
eﬀective if regular sinus rhythm was restored and the clinical
status improved, partially eﬀective if the arrhythmia persisted but
the ventricular rate slowed and symptoms improved and inef-
fective if arrhythmias and symptoms persisted [4]. Time to
arrhythmia control was deﬁned as time from intravenous loading
dose to sinus rhythm without any tachycardia episodes. The
Table 1 Characteristics of the study group of 23 infants. Variables
are number of patients or median and range
Variable
Age (days) 8 (1–300)
Weight (kg) 3.5 (2.4–8.2)
Follow-up (months) 18 (1–72)
Intrauterine tachycardias 4
Cardiac anatomy
Structurally normal heart 10
Congenital heart disease 10
Cardiomyopathy 3
Cardiac surgery 8
Symptoms
Respiratory distress 10
Post-operative haemodynamic instability 8
Cyanosis 2
Syncope/resuscitation 2
No symptoms 1
Table 2 Characteristics of arrhythmias and amiodarone therapy in
23 children. Variables are number of patients or median and range.
(AET atrial ectopic tachycardia, AFib atrial ﬁbrillation, AVRT
atrioventricular re-entrant tachycardia, IART intra-atrial re-en-
trant tachycardia, VT mon monomorphic ventricular tachycardia,
VT poly polymorphic ventricular tachycardia)
Arrhythmias N Patients after
previous cardiac
surgery
Heart rate pre
therapy (bpm)
Heart rate
on therapy (bpm)
Therapy
eﬀectivea
Time to
eﬀect (h)
Maximum iv
amiodarone dose
(lg/kg per min)
Days of iv
amiodarone
AVRT 8 2 248 (212–269) 135 (100–155) 7 39 (7–96) 15 (5–20) 5 (1–12)
AET 4 1 194 (157–227) 123 (111–131) 3 (1) 24 (3–63) 13.8 (7–16) 11 (4–14)
IART 4 3 182 (150–283) 129 (115–144) 4 7.5 (1–24) 10 (8–15) 3.5 (1–6)
AFib 1 0 300 152 (1) 24 5.0 3.0
VT mon 4 2 208 (165–211) 137 (132–154) 4 21.5 (8–40) 15 (5–15) 7.8 (3–24)
VT poly 2 0 284 (198–370) 150 (149–151) 1 (1) 1 15.5 (5–26) 8.5 (3–14)
All patients 23 8 224 (150–370) 134 (100–155) 19 (3) 24 (1–96) 15 (5–26) 5 (1–24)
aIn brackets number with partial eﬀect
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evaluation of pro-arrhythmic eﬀects was based on previous def-
initions but included also a QTc prolongation >500 ms in the
absence of pre-excitation, bundle branch block or intraventricu-
lar block [12]. Neurological, liver or thyroid dysfunction and
haemodynamic eﬀects necessitating amiodarone dosage reduction
or cessation of drug administration were considered as signiﬁcant
side-eﬀects. Ophthalmological follow-up was not performed in
infants as the examination had to be done under general
anaesthesia which was considered to be inadequate for a 1-year
treatment period.
Statistics
Data were analysed by using descriptive statistics and expressed as
median and range. A non-paired student t -test was used where
applicable. A P value of <0.05 was considered statistically sig-
niﬁcant.
Results
Arrhythmia control
Details of arrhythmias and amiodarone therapy are
described in Table 2. Intravenous amiodarone was given
to 23 infants, 17 with incessant supraventricular tachy-
cardias and ejection fraction <45% or haemodynamic
instability (eight post-operative) and six for incessant
ventricular tachycardias. Intravenous amiodarone was
eﬀective or partially eﬀective in 22 of 23 patients. Partial
eﬀects in three infants consisted of tachycardia rate
slowing in a polymorphic ventricular tachycardia and an
atrial ectopic tachycardia, and ongoing non-sustained
runs of atrial tachycardia in an infant with cardiomyo-
pathy and atrial ﬁbrillation respectively. The partial
eﬀect of slowing the tachycardia rate in two infants al-
lowed to stabilise them haemodynamically and then to
control the arrhythmia with a combination therapy
adding oral propafenone to oral amiodarone. No eﬀect
was achieved in an infant with atrioventricular re-
entrant tachycardia.
In 12 patients with marked haemodynamic insta-
bility, anti-arrhythmic therapy was possibly jeopar-
dised by the concomitant administration of vasoactive
substances or inotropes. However, the concomitant use
of these potentially pro-arrhythmic agents did not
inﬂuence eﬃcacy, time to arrhythmia control or re-
quired amiodarone dosages (amiodarone maintenance
dosage 12.2 ± 4.6 lg/kg per min without inotropes
versus 12.1 ± 6.1 lg/kg per min with inotropes,
P = 0.95).
Although intravenous amiodarone produced tachy-
cardia slowing in the loading phase and early mainte-
nance phase, the time to control the arrhythmia
completely in the case of atrioventricular re-entrant
tachycardia runs was up to 96 h. However, as all pa-
tients with eﬀective or partially eﬀective amiodarone
therapy had improved already haemodynamically with
rate slowing, no further concomitant anti-arrhythmic
agents were used.
Drug side-eﬀects
A marked QTc prolongation was seen in most patients
with a median QTc of 428 ms (range 397–569 ms) after
the intravenous drug loading dose compared to a med-
ian QTC of 476 ms (range 375–576 ms) at hospital dis-
charge. However, as concomitant drugs and rhythm
changes also inﬂuenced the repolarisation, no mean-
ingful statistical analyses can be obtained about the
signiﬁcance of the QTc prolongation. QTc >500 ms
were only seen in infants with bundle branch block,
intraventricular block and Wolﬀ-Parkinson-White syn-
drome. Maintenance dosages of 12.5 and 15 lg/kg per
min caused sinusbradycardia around 100 beats per
minute in two infants, however, resolved after dose
reduction. Mild hypotension was seen in one patient on
a maintenance dosage of 10 lg/kg per min which also
resolved after dose reduction. Markedly elevated liver
enzymes were observed and considered as a side-eﬀect in
an infant after arterial switch operation. As a potential
liver toxic agent, amiodarone therapy was stopped in
this patient whose arrhythmia had been controlled.
Choreatic movements in one infant who presented with
cardiogenic shock resolved over time under ongoing
oral amiodarone therapy. Thyroid toxicity with T4 or
TSH values outside the reference range for age was not
observed.
Follow-up
In 22 infants, long-term amiodarone therapy was
established with a median oral amiodarone dosage of
9 mg/kg per day (range 5–15 mg/kg per day). Combi-
nation therapies with oral propafenone were instituted
in two patients with partial intravenous amiodarone
eﬀect and in two patients who showed tachycardia
breakthroughs on oral amiodarone. Oral amiodarone
therapy was continued for a median period of 12 months
(range 1–31 months). Arrhythmias resolved spontane-
ously in 17 infants or did not need further treatment in
one infant. Thyroid dysfunction or elevated liver en-
zymes were not observed in infants on oral amiodarone
treatment. During up to 72 months of follow-up, ﬁve
infants died unrelated to amiodarone therapy, three with
dilative cardiomyopathy due to pump failure, one due to
other congenital malformations and one due to cerebral
bleeding while on anticoagulant therapy.
Discussion
Arrhythmia control
Intravenous amiodarone was given to 23 newborns and
infants with incessant, life-threatening supraventricular
and ventricular tachycardias because of its high anti-
arrhythmic eﬃcacy combined with low negative inotro-
pic eﬀect [3, 4,7]. Although there was a large spectrum of
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arrhythmias, six infants presented with ventricular
tachycardias. More than 50% of the patients had con-
genital heart disease or cardiomyopathies and eight in-
fants had undergone cardiac surgery. With a median age
of 8 days, the majority of patients were very sick new-
borns who were haemodynamically unstable. Never-
theless, intravenous amiodarone was very eﬀective and
terminated the tachycardias in 19 of 23 infants. A partial
eﬀect in three infants allowed haemodynamic stabilisa-
tion. These success rates are comparable to other studies
including older paediatric patients [1, 3, 4,6]. However,
the high success rate in arrhythmia control despite pro-
arrhythmogenic drug applications, electrolyte shifts and
increased sympathetic drive due to post-operative stress
in some patients, is remarkable. Noteworthy is also that
intravenous amiodarone did not aggravate haemody-
namic instability.
Amiodarone administration
Although amiodarone was given intravenously, it took a
median time of 24 h to control the arrhythmia which
may seem a long time in a life-threatening situation.
Other groups also observed similar time periods until
arrhythmia control [4]. However, as all patients had al-
ready improved haemodynamically in the intravenous
drug loading or early maintenance phase by rate slowing
of the tachycardia, a premature change in anti-arrhyth-
mic management was avoided. Compared to published
drug dosage recommendations, the median required
intravenous maintenance dosage of 15 lg/kg per min is
high. This may be a consequence of poor perfusion in
haemodynamically compromised patients with slow tis-
sue uptake and not a countereﬀect of inotropes as the
required maintenance dosage was similar in patients
with and without inotropic support. However, it ap-
peared that the maximum eﬀective intravenous mainte-
nance dosage is in the range of 20–25 lg/kg per min. As
in other reports, the median time of 5 days intravenous
amiodarone demonstrates also the major eﬀort required
to stabilise the patients haemodynamically and to
guarantee absorption of the drug when intravenous
amiodarone is replaced by oral amiodarone [4].
Safety of amiodarone
Intravenous amiodarone proved to be a safe therapy in
infants. Like in other studies, no severe pro-arrhythmic
eﬀects were seen [3]. Sinus bradycardia could be easily
resolved by dosage reduction. QTc prolongations
>500 ms were only seen in patients with abnormal
depolarisation such as Wolﬀ-Parkinson-White syndrome
and intraventricular or bundle branch block. Systemic
side-eﬀects like hypotension in one patient could be
adequately recognised and resolved by dose reduction.
Thus, there was little indication of a marked negative
inotropic eﬀect of intravenous amiodarone. Compared
to reports concerning hypotension following bolus
administration of intravenous amiodarone in adults, the
rarity of hypotensive side-eﬀects in our patients demon-
strates the haemodynamically better tolerance of loading
and maintenance infusions. However, newer aqueous
intravenous amiodarone solutions lacking hypotensive
solvents may minimise the risk of hypotension even
further [5,11]. Despite the mild pro-arrhythmic and
haemodynamic side-eﬀects, a close cardiovascular mon-
itoring in an intensive care setting of all patients receiving
intravenous amiodarone is strongly recommended. Ele-
vated liver enzymes in one patient after cardiac surgery
was possibly due to a combination of liver toxic eﬀects.
Amiodarone cessation may be warranted in such patients
in order to avoid further liver damage. Choreatic
movements in one patient resolved over time. Although a
transient neurological complication occurred in only a
single infant other studies indicate that neurological side-
eﬀects of amiodarone and other anti-arrhythmic drugs
are far more common [2]. Further follow-up in 22 infants
after replacement with oral amiodarone did not reveal
signiﬁcant pro-arrhythmic eﬀects, elevated liver enzymes
or thyroid dysfunction. Due to the age of the patient
group, photosensitivity with skin discolouration was not
an issue. As amiodarone therapy was only meant to be a
temporary anti-arrhythmic therapy up to about a year,
long-term side-eﬀects such as cornea deposits or pul-
monary ﬁbroses were not expected [3].
In this study with a small number of patients, intrave-
nous amiodarone was a safe and eﬀective therapy for life-
threatening incessant tachycardias in infants. However,
taking the various potential side-eﬀects into consider-
ation, intravenous amiodarone therapy should still be
reserved for those infants with incessant tachycardias and
severe haemodynamic compromise in whom D/C car-
dioversion, overdrive pacing or intravenous adenosine is
not successful or not applicable. Further studies are nee-
dedbeforedeﬁnitive recommendations canbemadeabout
the administration of amiodarone in infants.
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